Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
You are in: eMedicine Specialties > Emergency Medicine > Genitourinary

Urinary Tract Infection, Male

Last Updated: April 25, 2005
Email to a Colleague
Synonyms and related keywords: cystitis, pyelonephritis, Escherichia coli infection, gonococcal urethritis, nongonococcal urethritis, prostatitis, epididymitis, orchitis, dysuria, urgency, frequency, nocturia, hematuria, prostatic enlargement, urinary dribbling, urinary hesitancy, indwelling catheters, nephrolithiasis, neurogenic bladder, meatal discharge, scrotal hematoma, hydrocele, costovertebral angle tenderness, CVA tenderness, tenderness in suprapubic area, prostatic tenderness, prostatic hypertrophy

  AUTHOR INFORMATION Section 1 of 10    Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Author: David S Howes, MD, Residency Program Director, Professor of Medicine, Section of Emergency Medicine, University of Chicago/Pritzker School of Medicine

Coauthor(s): Steven S Kantor, MD, Staff Physician, Clinical Instructor, Section of Emergency Medicine, University of Chicago; Stephen Fines

David S Howes, MD, is a member of the following medical societies: American College of Emergency Physicians, American College of Physicians-American Society of Internal Medicine, and Society for Academic Emergency Medicine

Editor(s): Joseph A Salomone III, MD, Associate Professor, Department of Emergency Medicine, Truman Medical Center, University of Missouri at Kansas City School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Richard Sinert, DO, Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; and Scott H Plantz, MD, FAAEM, Research Director, Assistant Professor, Department of Emergency Medicine, Mount Sinai School of Medicine

Disclosure


  INTRODUCTION Section 2 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Background: The consideration of male urinary tract infection (UTI) is complicated by the overlap with what might be termed reproductive tract infections. For the purposes of this article, the male UTI includes infections that arise from bacterial colonization of the urinary tract proper (ie, kidney, ureter, bladder). Infections of contiguous structures, for example, urethritis, epididymitis, prostatitis, or orchitis, are covered in other articles.

Pathophysiology: As with females, the usual route of inoculation in males is with gram-negative aerobic bacilli from the gut, with Escherichia coli being the most common offending organism. In males aged 3 months to 50 years, incidence of UTI is low; therefore, the possibility of anatomical abnormalities must be entertained in this age group.

Frequency:

  • In the US: The frequency of male UTI is related to age.
  • Internationally: In developed countries, the incidence of UTI in males is similar to that in the United States. However, in developing countries where men have shorter life spans, the incidence of UTI due to prostatic hypertrophy is lower.

Mortality/Morbidity: Otherwise healthy males without anatomical abnormalities who promptly seek treatment experience little morbidity besides the discomfort of an infection.

  • In more complicated cases (eg, prolonged infection, anatomical variations), the sequelae of infection can be more significant. Complications include strictures secondary to inflammation within the urinary tract, abscess and fistula formation, bacteremia, and a deleterious effect on kidney function.
  • In elderly patients, UTI is a significant cause of morbidity and death, with the expected death rate as high as 3% in those who develop pyelonephritis. The high mortality rate is largely due to delayed presentation and the development of bacteremia/sepsis.

Sex: Although this article exclusively addresses UTI in males, the clinician should appreciate that the incidence of UTI is much higher in females during adolescence and childbearing years. The incidence of UTI in men approaches that of women only in men older than 60 years.

Age: The incidence of UTI has an early peak during the first 3 months of life. In neonates, a UTI occurs more frequently in boys than in girls (with a male-to-female ratio of 1.5:1), and it is often part of the syndrome of gram-negative sepsis.

  • The cumulative incidence of symptomatic UTI (including pyelonephritis) in boys during the first 10 years of life has been reported at 1.1-1.6%.
  • The incidence of true UTI in adult males younger than age 50 years is low (approximately 5-8 per year per 10,000). In this population, the symptoms of dysuria or urinary frequency are usually due to sexually transmitted disease (STD)–related infections of the urethra (eg, gonococcal and nongonococcal urethritis) and prostate.
  • In men older than 50 years, the incidence of UTI rises dramatically because of enlargement of the prostate, prostatism, and subsequent instrumentation of the urinary tract.


  CLINICAL Section 3 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

History:

  • The most frequent chief complaint with UTI is dysuria.
  • Other aspects to inquire about include urgency, frequency, nocturia, gross hematuria, and any changes in the color and/or consistency of the urine.
  • Associated signs and symptoms include fever, chills, back/flank pain, suprapubic pain, and nausea and vomiting.
  • Ask elderly men about a history of prior UTI, prostatic enlargement, urinary dribbling or hesitancy, or difficulty initiating the urinary stream.
  • Ask all men about known urinary tract abnormalities, personally and within their families, as well as any history of prior UTI.
  • Particularly in elderly patients, inquire about prior urinary tract manipulation, history of indwelling catheters, or other chronic urinary tract problems; these patients are at much higher risk of UTI.
  • Other relevant items in the history include comorbid conditions (eg, diabetes), HIV status, immunosuppressive treatments for other conditions (eg, prednisone), and any prior surgeries or instrumentation involving the urinary tract.
  • One of the difficulties in diagnosing UTI in males lies in the fact that dysuria, with or without discharge, is the typical chief complaint with urethritis, which is a much more common disease. Determining the history of urinary and genital tract symptoms and sexual encounters, combined with laboratory testing of urine and urethral swabs, should allow differentiation of the two.
  • Classic findings with pyelonephritis include fever, chills, and costovertebral angle (CVA) tenderness that follow the symptoms of UTI. Note that 30-50% of pyelonephritis cases may be silent, without clinical symptoms.
    • In the elderly man, prostate enlargement along with delayed presentation are the primary causes of pyelonephritis.
    • Other historical risk factors include nephrolithiasis, neurogenic bladder, prostatitis, or symptom duration greater than 5 days.
  • In the younger man, anatomical abnormalities and a complete sexual history are the most useful historical details.

Physical:

  • Fever
  • Tachycardia
  • CVA tenderness (bruits)
  • Abdominal tenderness in the suprapubic area and guarding (pulsatile masses in elderly patients)
  • Scrotal hematoma, hydrocele, masses, or tenderness
  • Meatal discharge
  • Rectal lesions or abscesses
  • Prostatic tenderness or hypertrophy
  • Inguinal adenopathy

Causes:

  • UTI in males typically is caused by bacterial colonization of the urinary tract, though fungal or other types of infection are possible.
  • The sources of these bacteria or other agents can vary. Routes of infection include the following:
    • Direct ascension up the urinary tract via the urethra
    • Hematogenous spread, as with bacteremia
    • Spreading from contiguous structures, such as the prostate
    • Iatrogenic instrumentation
  DIFFERENTIALS Section 4 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Aneurysm, Abdominal
Appendicitis, Acute
Back Pain, Mechanical
Chlamydia
Constipation
Diverticular Disease
Epididymitis
Gastritis and Peptic Ulcer Disease
Gastroenteritis
Gonorrhea
Inflammatory Bowel Disease
Obstruction, Large Bowel
Obstruction, Small Bowel
Orchitis
Prostatitis
Renal Calculi
Testicular Torsion
Trauma, Lower Genitourinary
Trauma, Upper Genitourinary
Urethritis, Male


Quick Find
Author Information
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
Bibliography

Click for related images.

Related Articles
Aneurysm, Abdominal

Appendicitis, Acute

Back Pain, Mechanical

Chlamydia

Constipation

Diverticular Disease

Epididymitis

Gastritis and Peptic Ulcer Disease

Gastroenteritis

Gonorrhea

Inflammatory Bowel Disease

Obstruction, Large Bowel

Obstruction, Small Bowel

Orchitis

Prostatitis

Renal Calculi

Testicular Torsion

Trauma, Lower Genitourinary

Trauma, Upper Genitourinary

Urethritis, Male


Patient Education



  WORKUP Section 5 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Lab Studies:

  • Obtain the urine sample first.
    • If the patient is able, a routine voiding sample is adequate.
    • If this is not available, a catheterized specimen is necessary.
  • Positive urinalysis findings include leukocytes and bacteria in an otherwise uncontaminated urine specimen.
    • The threshold for establishing true UTI includes finding greater than or equal to 2-5 WBCs or 15 bacteria per high power field (HPF) in a centrifuged urine sediment.
    • In younger men, differentiation of UTI from urethritis may necessitate a urethral smear; cultures for chlamydia and Neisseria gonorrhoeae should be sent.
    • The decision to treat young men who are sexually active for UTI versus STD-related urethritis rests primarily on epidemiologic grounds (eg, recent new sexual partner, multiple sexual partners). In males aged 15-50 years, UTI is more common in males with anatomic abnormalities; in the sexually active male with no urinary tract abnormalities, STD-related urethritis predominates, although UTI may occasionally be diagnosed.
  • Obtain a urine culture for all males with UTI. This allows modification of treatment plans if antibiotic sensitivity testing demonstrates a resistant organism. A urine culture for a male is considered positive if it has >1000 colony-forming units/mL of urine, much lower than the threshold for women.

Imaging Studies:

  • In males younger than 50 years, referral to a urologist or a nephrologist is appropriate.
    • If an anatomic abnormality or complicating obstructing stone is suspected based on history and physical examination, imaging of the urinary system to exclude hydronephrosis is appropriate.
    • Modalities for this include ultrasound, intravenous pyelography (IVP), contrasted computed tomography (CT scan), or helical computed tomography (HelCT scan) of the urinary system.

Other Tests:

  • For UTI, the tests outlined above should be adequate. Other tests will be needed if the physician is unsure of the diagnosis and needs to rule out other items on the differential list.
  • In the older man in whom prostatism is suspected, measurement of the post voiding residual urine volume is very important.
    • Although traditionally done via catheterization, some institutions are now using ultrasound for this measurement.
    • No other diagnostic imaging studies exist, though the urologist may perform additional studies (eg, cystoscopy).
  TREATMENT Section 6 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Emergency Department Care: As a general rule, all UTIs in men are considered complicated; the possibility that infection has ascended to the kidneys must be assumed.

Patients who are well appearing, have stable vital signs, are able to maintain oral hydration and comply with oral therapy, and have no significant comorbid conditions can be discharged home with adequate follow-up arranged in 48-72 hours.

If the patient appears toxic, is unable to tolerate fluids by mouth, has significant comorbid disease, or otherwise is unable to care for himself at home, consider inpatient admission.

Consultations: In adult males with a UTI, an underlying anatomical abnormality should be suspected. Consultation with a urologist is necessary. However, this can be done on an outpatient basis.
  MEDICATION Section 7 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

The goals of treatment are to resolve infection of the upper and lower urinary tract and relieve the signs and symptoms associated with UTI in the male patient.

Drug Category: Antibiotics -- Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.
Drug Name
Sulfamethoxazole-trimethoprim (Bactrim, Septra) -- Inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. Results in inhibition of bacterial growth.
Antibacterial activity of TMP-SMZ includes common urinary tract pathogens, except Pseudomonas aeruginosa.
Adult Dose160 mg TMP/800 mg SMZ PO q12h for 10-14 d
Pediatric Dose<2 months: Do not administer
>2 months: 8 mg/kg TMP/40 mg/kg SMZ divided bid
ContraindicationsDocumented hypersensitivity; megaloblastic anemia caused by folate deficiency; pregnant patients at term; breastfeeding mothers
Interactions Warfarin may increase PT (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; diuretics increase incidence of thrombocytopenia purpura in elderly; may increase phenytoin levels; may potentiate effects of methotrexate in bone marrow depression; may increase hypoglycemic response to sulfonylureas; may increase levels of zidovudine
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsDiscontinue at first appearance of skin rash or sign of adverse reaction; obtain CBCs frequently; discontinue therapy if significant hematologic changes occur; sulfonamides may cause goiter production, diuresis, and hypoglycemia; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, give 5-15 mg/d leucovorin); AIDS patients may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); administer fluids to prevent crystalluria and stone formation
Drug Name
Ciprofloxacin (Cipro) -- Indicated for pseudomonal infections and infections due to multidrug-resistant gram-negative organisms.
Adult Dose250-500 mg PO bid for 10-14 d
Pediatric Dose<18 years: Not recommended
>18 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsAntacids, iron salts, and zinc salts may interfere with GI absorption, resulting in decreased serum levels (administer antacids 2-4 h before or after fluoroquinolone); cimetidine may interfere with metabolism; may reduce therapeutic effects of phenytoin; probenecid may significantly increase serum concentrations; may increase theophylline and caffeine concentrations and prolong their duration of action; may increase nephrotoxic effect of cyclosporine; may increase digoxin serum levels (monitor digoxin levels); may increase effects of anticoagulants (monitor PT)
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsIn prolonged therapy, perform periodic evaluations of organ system functions including renal, hepatic, and hematopoietic; patients with renal function impairment may require dose adjustment; prolonged or repeated antibiotic therapy may result in bacterial or fungal overgrowth of nonsusceptible organisms, resulting in secondary infections; take appropriate measures to prevent further complications
Drug Name
Ceftriaxone (Rocephin) -- Third-generation cephalosporin that has broad gram-negative spectrum, lower efficacy against gram-positive organisms, and higher efficacy against resistant organisms. By binding to one or more penicillin-binding proteins, arrests bacterial cell wall synthesis and inhibits bacterial growth.
Adult DoseSevere infections: 1-2 g IV qd or divided bid; not to exceed 4 g/d
Pediatric DoseSerious infections: 50-75 mg/kg/d IV divided bid; not to exceed 2 g/d
ContraindicationsDocumented hypersensitivity
InteractionsAminoglycosides increase nephrotoxic potential; probenecid increases effects by decreasing clearance
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in severe renal impairment
Drug Name
Gentamicin (Garamycin, Gentacidin) -- Aminoglycoside used for gram-negative bacterial coverage. Commonly used in combination with both agent against gram-positive organisms and one that covers anaerobes. Consider using when penicillins or other less-toxic drugs are contraindicated, when bacterial susceptibility tests and clinical judgment indicate its use, and in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. Dosing regimens are numerous and are adjusted based on creatinine clearance and changes in volume of distribution.
Adult DoseSerious infections and normal renal function: 3 mg/kg IV/IM q8h
Extended dosing regimen for life-threatening infections: 5 mg/kg IV/IM q6-8h
Follow each regimen by at least a trough level drawn on third or fourth dose (0.5 h before dosing); may draw peak level 0.5 h after 30-min infusion
Pediatric Dose<5 years with normal renal function: 2.5 mg/kg IV/IM q8h
>5 years: 1.5-2.5 mg/kg IV/IM q8h or 6-7.5 mg/kg/d IV/IM divided q8h; not to exceed 300 mg/d; monitor levels as in adults
ContraindicationsDocumented hypersensitivity; non–dialysis-dependent renal insufficiency
InteractionsOther aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxic potential; may increase effects of neuromuscular blocking agents (prolonged respiratory depression may occur); loop diuretics may result in increased auditory toxicity (hearing loss of varying degrees may occur and may be irreversible; monitor patients regularly)
Pregnancy D - Unsafe in pregnancy
PrecautionsBecause of narrow therapeutic index and toxicity associated with extended administration, not recommended for long-term therapy; exercise caution when administering to patients with renal failure (not on dialysis), hypocalcemia, myasthenia gravis, or conditions that depress neuromuscular transmission; adjust dose in patients with renal impairment
Drug Name
Ertapenem (Invanz) -- Bactericidal activity results from inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins. Stable against hydrolysis by a variety of beta-lactamases including penicillinases, cephalosporinases, and extended spectrum beta-lactamases. Hydrolyzed by metallo-beta-lactamases.
Adult Dose1 g qd for up to 14 d if given IV and up to 7 d if given IM; infuse over 30 min if given IV
Pediatric DoseNot established; use in patients <18 years old is not recommended
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid may reduce renal clearance of ertapenem and increase half-life but benefit is minimum and does not justify coadministration
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsPseudomembranous colitis may occur; seizures and CNS adverse reactions may occur; when using with lidocaine to administer intramuscularly, avoid inadvertent injection into blood vessel
Drug Category: Analgesics -- Analgesics are indicated for the initial treatment of mild to moderately severe pain associated with UTI.
Drug Name
Phenazopyridine (Pyridium, Urogesic) -- Azo dye is excreted in urine, where it exerts topical analgesic effect on urinary tract mucosa. Compatible with antibacterial therapy and can help relieve pain and discomfort before antibacterial therapy controls infection. Used for symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures or passage of sounds or catheters. Analgesic action may reduce or eliminate need for systemic analgesics or narcotics.
Adult Dose100-200 mg tid PO for 2 d
Pediatric Dose<6 years: Not established
6-12 years: 12 mg/kg/d divided tid PO for 2 d
>12 years: Administer as in adults
ContraindicationsDocumented hypersensitivity; renal insufficiency
InteractionsNone reported
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsCaution in renal insufficiency; yellowish tinge of skin or sclerae may indicate accumulation because of impaired renal excretion (discontinue therapy if this occurs); treatment of UTI with phenazopyridine should not exceed 2 d because no evidence indicates that is more beneficial than antibiotic alone following 2 d of therapy
  FOLLOW-UP Section 8 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Further Inpatient Care:

  • As noted in Emergency Department Care, consider admission for elderly patients and patients who have diabetes, who are immunocompromised, or who show signs of toxicity such as dehydration, hyperpyrexia, rigors, or inability to tolerate oral fluids or medications. Also admit if the patient is unable to care for himself.
  • Administer IV fluids sufficient to restore adequate circulating volume and treat dehydration or shock.
  • Administer antimicrobial therapy, initially given intravenously, such as a third-generation cephalosporin, a fluoroquinolone, or an aminoglycoside. In patients with risk factors associated with an unfavorable prognosis, such as old age, debility, renal calculi, recent hospitalization or instrumentation, diabetes, sickle cell anemia, underlying carcinoma, or intercurrent cancer chemotherapy, the antimicrobial coverage should be broadened and an antipseudomonal agent should be added.
  • Provide supportive management with antipyretics and pain medications.

Complications:

  • Consider the presence of a complicating urinary calculus with obstructing hydronephrosis in the patient with clinically apparent pyelonephritis.
  • The older patient who appears toxic, has diabetes, or is immunocompromised may be at risk for emphysematous pyelonephritis; radiographic studies (eg, KUB) may be necessary to exclude this possibility.
  • If prostatism and a high residual volume are suspected, the volume of postvoid residual urine must be determined. If it is elevated, then a urinary catheter must be placed and urologic consultation obtained.

Prognosis:

  • The following conditions or settings increase the rates of mortality and morbidity associated with UTI in men:
    • Older patients who present with signs of dehydration, hypoperfusion, or overt shock
    • Complicating urinary obstruction due to calculi
    • Recent urinary tract instrumentation, hospitalization, or broad-spectrum antibiotic therapy
    • Development of emphysematous pyelonephritis
    • Patients who are older and have diabetes or are immunocompromised

Patient Education:

  MISCELLANEOUS Section 9 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Medical/Legal Pitfalls:

  • Young men have a very low incidence of UTI. If UTI is diagnosed frequently in a young man, the physician is overlooking the far more likely STD-related urethritis/prostatitis.
  • Treatment regimens must assume that infection of the upper urinary tract has occurred.
  • In elderly patients, pyelonephritis carries a 3% mortality rate. Take a conservative management approach with these patients.
  • Failure to consider an obstructing urinary calculus results in delay of inpatient consultation with a urologist in the septic elderly patient.
  • Patients with diabetes and those with recent urinary tract instrumentation, recent hospitalization, or taking broad-spectrum antibiotics have an increased incidence of resistant organisms.
  BIBLIOGRAPHY Section 10 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

  • Anandkumar H, Kapur I, Dayanand A: Increasing prevalence of antibiotic resistance and multi drug resistance among uropathogens. J Commun Dis 2003 Jun; 35(2): 102-8[Medline].
  • Daunt SW: Accuracy of ultrasonography and plain-film abdominal radiography in the diagnosis of urologic abnormalities in men with urinary tract infection: critically appraised topic. Can Assoc Radiol J 2004 Feb; 55(1): 16-7[Medline].
  • Foxman B: Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002 Jul 8; 113 Suppl 1A: 5S-13S[Medline].
  • Ginde AA, Rhee SH, Katz ED: Predictors of outcome in geriatric patients with urinary tract infections. J Emerg Med 2004 Aug; 27(2): 101-8[Medline].
  • Griebling TL: Urologic diseases in america project: trends in resource use for urinary tract infections in men. J Urol 2005 Apr; 173(4): 1288-94[Medline].
  • Hooton TM: The current management strategies for community-acquired urinary tract infection. Infect Dis Clin North Am 2003 Jun; 17(2): 303-32[Medline].
  • Howes DS, Bogner MP: Urinary tract infections. In: Tintinalli JE et al, eds. Emergency Medicine: A Comprehensive Study Guide. 6th ed. New York: McGraw-Hill; 2004:606-612.
  • Howes DS, Remer EE: Male urologic infections. In: Harwood-Nuss AL et al, eds. Clinical Practice of Emergency Medicine. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001:267-272.
  • Hummers-Pradier E, Ohse AM, Koch M, et al: Urinary tract infection in men. Int J Clin Pharmacol Ther 2004 Jul; 42(7): 360-6[Medline].
  • Johnson JR: Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis 2004 Sep 15; 39(6): 873; author reply 873-4[Medline].
  • Killgore KM, March KL, Guglielmo BJ: Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004 Jul-Aug; 38(7-8): 1148-52[Medline].
  • Sanford JP: Guide to Antimicrobial Therapy. Dallas, Tex: Antimicrobial Therapy Inc; 2004.
  • Thompson PDR: Physicians' Desk Reference. 2005.
  • Weir M, Brien J: Adolescent urinary tract infections. Adolesc Med 2000; 11: 293-313[Medline].
  • Wells WG, Woods GL, Jiang Q, Gesser RM: Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother 2004 Jun; 53 Suppl 2: ii67-74[Medline].

Urinary Tract Infection, Male excerpt